Persistence of mild hyperthyrotropinemia after discontinuation of three-year course of low-dose @entity1955 therapy in XXXX with @entity1375 .

@entity1 @entity1375 @entity1955 @entity2016 @entity1218
Treatment plan for neonates with @entity1375 (persistent hyperthyrotropinemia with normothyroxinemia) has not been established. In this study, changes in thyroid function after discontinuation of low-dose @entity1955 ( @entity2016 ) supplement in @entity1 with the condition were evaluated. Fourteen @entity1 with hyperthyrotropinemia at neonatal screening had repeated hyperthyrotropinemia (> 8 mU/L) with normothyroxinemia. TSH response was exaggerated at TRH testing. The subjects were treated with low-dose @entity2016 (3 to 9 microg/kg/day) for 2.2 to 6 years, and euthyroid status was maintained. After discontinuation of therapy, mild hyperthyrotropinemia persisted up to 24 months, while serum FT4 remained within the lower half of the normal range. TSH response to @entity1218 stimulation, which tended to be exaggerated 1 month after discontinuation, became lower 6 to 12 months later. RAIU and thyroid scintigraphy were normal in all subjects. No @entity1 developed hypothyroxinemia, although mild elevation of TSH lasted rather long after discontinuation of low-dose @entity2016 therapy. Administration of @entity2016 was not resumed provided the subjects were followed at regular interval. Further long-term investigation is needed to define whether re-administration is necessary or not.
